ArticleCurrent medicinal chemistry2026
Determination of the 95% Effective Dose of Remifentanil for Moderate Sedation During Gastroscopy in Obese Patients.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionObesity increases the risk of hypoxemia during gastroscopy. The optimal remifentanil dose for effective and safe conscious sedation in this population remained unclear. Applying the biased coin design up-and-down sequential method, we aimed to determine the 95% Effective Dose (ED MATERIALS AND
methodsIn this prospective interventional dose-finding study, patients aged 18-65 years with a BMI ≥ 30 kg/m2 (ASA class I-III) undergoing elective gastroscopy received remifentanil via target-controlled infusion. Patients with opioid allergy were excluded. A biased coin design-up-and-down method was used to determine the dosage, and the ED95 was estimated using isotonic regression. Ramsay sedation scores, Visual Analog Scale (VAS) pain scores, vital signs, and satisfaction ratings were recorded.
resultsForty-two patients were enrolled. Sedation was successful in 83.3% (35/42) of patients. The estimated ED95 of remifentanil was 0.915 μg/kg (95% CI: 0.790-0.989). The mean procedure time was 5.85 minutes. Hypoxemia occurred in 4.8% (n = 2, lowest SpO DISCUSSION: This study found that remifentanil monotherapy can serve as an effective and safe strategy for conscious sedation in obese patients undergoing gastroscopy. We determined the effective dose ED95 to be 0.915 μg/kg (95% CI, 0.790-0.989), providing a potential evidence-based starting point for clinical practice. The favorable safety profile, characterized by a low incidence of hypoxemia, addressed a critical need for sedation strategies that minimize respiratory depression in this high-risk population. Future research should explore combinations with non-opioid adjuvants to further reduce opioid- related adverse effects and incorporate objective respiratory monitoring, such as capnography, to enhance safety assessment.
conclusionRemifentanil monotherapy provided effective conscious sedation for gastroscopy in obese patients, showing a high success rate and low incidence of hypoxemia. The ED95 was determined to be 0.915 μg/kg.
Indexed as
Identifiers
42003097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.